PATENT CLAIM ANALYSIS

Application Number: 15901412
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "010900"]

Abstract:
Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

Claim (Index 16):
A method of increasing blood pressure in a human in need thereof, the method comprising:\n a) providing a pharmaceutical composition for intravenous administration comprising: i) from about 0.01 mg/mL to about 0.07 mg/mL of vasopressin or a pharmaceutically-acceptable salt thereof; optionally chlorobutanol; acetic acid, acetate, or a combination thereof; iv) 0-2% vasopressin degradation products; and v) water; wherein the pharmaceutical composition has a pH of 3.5 to 4.1; wherein the pharmaceutical composition is provided in a container;\n b) drawing from a dispensing region of the container a first time a first portion of the pharmaceutical composition; \n c) intravenously administering the first portion of the pharmaceutical composition to the human, \n wherein the administration provides to the human from about 0.01 units of vasopressin or the pharmaceutically acceptable salt thereof per minute to about 0.1 units of vasopressin or the pharmaceutically acceptable salt thereof per minute, wherein the human is hypotensive;\n d) drawing from the dispensing region of the container a second time a second portion of the pharmaceutical composition, \n wherein the second time that the second portion of the pharmaceutical composition is drawn from the container occurs at least 48 hours after the first time that the first portion of the pharmaceutical composition is drawn from the container; and\n e) intravenously administering the second portion of the pharmaceutical composition to the human, \n wherein the administration of the second portion of the pharmaceutical composition provides to the human from about 0.01 units of vasopressin or the pharmaceutically acceptable salt thereof per minute to about 0.1 units of vasopressin or the pharmaceutically acceptable salt thereof per minute.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 88.0
- Lexical Diversity: 1.41026
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15606442', '15289640', '15612649', '15688305', '15688326']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7850669176469993
- 35 USC 102 Novelty (BERT): 0.6406594665286894
- Combined Prediction Score: 0.7706261725351683
- Mean Citation Score: 433.828968
- Max Citation Score: 496.38043
- Similarity Product: 385.86550318129656

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test